Alexion Pharmaceuticals, Inc.’s Post

This new report on NHS-industry partnerships from The Association of the British Pharmaceutical Industry (ABPI) and NHS Confed is worth a quick flick (and looks beautiful). Partnering with industry is often put in the "too difficult" box - but it doesn't have to be, especially where there is a clear potential benefit to the people we serve. There's some practical tools in here to help NHS organisations work through some of the thornier issues with partnership too. #health #nhs #pharmaceutical https://lnkd.in/eufXvHYq

Who are the "Top 5 CRO's to watch in 2024"? 👀 Here's my pick and why..... 1. IQVIA - IQVIA operates in over 100 countries and has approximately 87,000 employees making the organisation one of the biggest in the space. 💊 2. Charles River Laboratories - Charles River was jointly named “Best Contract Research Organisation (with NJ Bio, Inc.) at the 10th Annual World ADC Awards 2023. 👩🔬 3. Syneos Health - Syneos Health® received the 2023 ViE (Vaccine Industry Excellence) Award and PM360 2023 Innovator in Clinical Trials. 👨🔬 4. Caidya - In 2023, Caidya won the CRO Leadership Award for Overall Capabilities at the CRO Leadership Awards. 🏅 5. TFS HealthScience - For the fourth consecutive year, TFS received a Silver Rating from EcoVadis in 2023, placing it in the top 8% for sustainability excellence, a distinction that reinforces TFS’s commitment to corporate sustainability. 🌳 Let me know your thoughts and who you would put in your Top 5 in the comments below ⬇ #top5 #cro #award #thoughts

Germany and France. Two fascinating and sophisticated markets whose teams are fully embracing our Growth Strategy’s ‘five principles of success’. If I had to call out one exemplary behaviour being modelled in both markets, it is the very clear adoption of ‘act with urgency over waiting’. Speed, agility and cross-functional collaboration are flagship principles in the pharmaceutical industry but never more so than when navigating a complex reimbursement landscape. Because the earlier we engage stakeholders in a product's lifecycle and the better we involve different functions in the process, the smoother the path to market access will be. It was enlightening and inspiring for Naoki Okamura (Astellas CEO), Damien Bailly (Head of Established Markets - Commercial), Alan McDougall (Head of Established Markets - Medical Affairs) and myself to see for ourselves the true impact of accelerating local decision-making. By empowering those closest to the customer to make faster decisions, Markus Weber (GM Germany), Ghislaine Leleu (GM France) and their teams are delivering more impactful solutions to the challenges that matter most, and in the process, bringing value to patients who are waiting. To the teams in Germany and France, thank you for showing up with the drive, passion and determination to make each and every day count.

Why do companies like Amgen, AbbVie, and Medtronic call Puerto Rico home? In this clip from #BIO2024, our CEO, Ella Woger-Nieves, shares why Puerto Rico is a top choice for global life sciences leaders. From a highly skilled workforce to a strategic location and business-friendly incentives, Puerto Rico offers unparalleled advantages for innovation and growth. Learn more ▶️ https://loom.ly/aaS5Ed0

Last week, USP welcomed a delegation of senior executives and leaders from Mexico's Asociación Mexicana de Laboratorios Farmacéuticos (AMELAF) in Rockville, MD. This meeting marks an important milestone in USP's ongoing engagement with industry leaders in Mexico, building upon AMELAF joining USP as a Convention member last year. The highlight of the meeting was the signing of a memorandum of understanding between AMELAF and USP, starting a new chapter of collaboration. • USP and AMELAF will establish a consistent channel for sharing vital insights on emerging quality challenges and best practices in effectively applying quality standards. • The organizations will collaborate on targeted training programs and knowledge-sharing activities aimed at strengthening quality assurance systems and standard-setting. • We will work together to advance long-term strategies promoting sustainable access to quality-assured medicines. By combining USP and AMELAF's expertise in standards-setting, shared goals, and local and global networks, the collaboration aims to accelerate progress toward delivering quality medicines to patients in Mexico and globally. Stay tuned for updates on this collaboration! Juan de Villafranca

🚀 Excited to announce that the Cognizant team will be participating and presenting at the upcoming EU World Drug Safety Congress in Amsterdam this October! 🎉 We will discuss two key topics that are crucial for the future of pharmacovigilance: 1️⃣ Why It’s Time to Bring Real-World Data into Pharmacovigilance to Enhance Patient Safety: We’ll explore the growing importance of incorporating real-world data into our safety practices, and why the industry must urgently adopt this approach to ensure better outcomes for patients. 2️⃣ Leveling the Playing Field in Pharmacovigilance for Mid-Sized and Small Pharma Organizations in 2024: This session will address the unique challenges smaller organizations face when trying to adopt automation and innovation due to cost and complexity. We'll delve into how a Full Service Provider (FSP) model can democratize access to these critical advancements. These discussions will cover both the strategic and operational aspects of pharmacovigilance, underscoring the need for industry-wide access to innovation and the critical role of real-world data in enhancing patient safety. Looking forward to engaging with fellow industry leaders and driving these conversations forward!

Congratulations to Dr. J. Jean Cui! With #lorlatinib's PFS reached more than 60 months (the PFS not reached yet, some estimated it could reach 10 years or more) and #repotrectinib's PFS reached 35.7 months, Jean's creativity (she designed both of the two FDA approved #oncology drugs) is helping transform deadly late-stage #cancer into manageable disease for ALK and ROS1 positive #NSCLC. More to come! https://lnkd.in/g4pSvZyC

Thoughts on this? >> Pfizer adds ex-State Street CEO to the board; Two Merus execs head for the exit >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #pharmaceutical #biotech #productmarketing

Thoughts on this? >> Pfizer adds ex-State Street CEO to the board; Two Merus execs head for the exit >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #pharmaceutical #biotech

Follow our new Fresenius Kabi Global Alliance Management page!